The Expanded Disability Status Scale (EDSS) and the Functional Systems Score (FSS) together describe severity of disability in patients with MS. With the help of the FSS, the examiner rates your disability on the EDSS scale. It ranges from 0 to 10, with half points for greater specificity. EDSS. • Expanded Disability Status Scale. – Devised by John Kurtzke in the s and modified A modification of the original Kurtzke scale.
|Published (Last):||26 March 2004|
|PDF File Size:||13.47 Mb|
|ePub File Size:||4.86 Mb|
|Price:||Free* [*Free Regsitration Required]|
Expanded Disability Status Scale (EDSS) | MS Unites – Multiple Sclerosis (MS) Information Portal
Mood alteration only Does not affect DSS score. The choose of medication changes from drug availability, introduction of new drugs in the market, Government supplied or preference for one of the several physicians in charge of patients over the years.
Or create a new account it’s free.
Moderate disability in one Function System and more than minimal disability in several others. The scale is sometimes criticized for its reliance on walking as the main measure of disability.
Essentially restricted to wheelchair; though wheels self in standard wheelchair and transfers alone. Able to walk without aid or rest for m 5. May be out of bed itself much of the day. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis: The progressive disability in multiple sclerosis MS remains a therapeutic problem despite numerous sgeet available.
He was a leading expert in the study of multiple sclerosis MS and a contributor in the creation of the field of neuroepidemiology. The EDSS scale is not a defacto mechanism but instead a fairly simplistic means and mechanism to measure MS disability rather broadband. Moderate nystagmus or other mild disability. The positive correlation of the EDSS with time of treatment and some sub-groups could be interpreted as progression of disability, while the negative correlation could be reduction or stabilization.
The Expanded Disability Status Scale EDSS is a method of calculating and understanding disability in multiple sclerosis patients as well as monitoring changes of disability over time. Thus a new scale of disability really needs to be created.
scire National Multiple Sclerosis Society; J Neurol Sci ; N Engl J Sgeet ; Defining the clinical course of multiple sclerosis: Another scors that used BET over a period of 16 years also showed a progression in disability, but demonstrated that individuals achieved the same degree of disability when using the medication for a period of 4.
This SYT group included newly diagnosed cases that had experienced a remission in clinical symptoms, a good therapeutic response to prednisone or methylprednisolone during relapses, a long interval between the second and third relapse, or side effects from other medications off IMS or IMM more than three months to be included in this groupor were from a period before the availability of IMM drugs or refused to use prescribed medications.
The difference from the initial and final EDSS score had statistical correlation with time of disease progression in months for the whole group of treatment, as well as for the sub-groups AZA and BET Pearson’s correlation r test, Table 4 and Fig 5.
These agents can reduce relapse rates and lesions observed by magnetic resonance imaging studies. STAT5 mediates acore effects of methylprednisolone on oligodencrocytes. This is probably the reason these individuals remained in the SYT group for several years. In situations when there is subjectivity and FS deficits do not correspond to a specific EDSS level, a range scorw provided.
When with the use shdet the MSSS, we found a reduction in We included only patients with a MS diagnosis who used different therapeutic procedures for their treatment. Moderate truncal or limb ataxia. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: Sensation essentially lost below the head.
Expanded Disability Status Scale (EDSS)
Some cases stabilized and even showed a reduction in long-term disability, according the type of scale used. The time of follow-up varied between 3 to months median 92, with a mean of During the follow-up, 78 cases had only one treatment type SYT edsss cases, AZA 20 cases, BET 22 cases, R22 20 cases, AVO 2 cases, R44 4 cases, COP 3 casesand the remaining 77 cases had two or more types of treatment at different times, but never at the same time 52 cases with two treatment types, 18 cases with three treatment types, 7 cases with 4 treatment types and 1 case with five treatment types.
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. About the Creator John F. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
We evaluated records, but 92 patients were excluded because their records were incomplete and it was not possible to assess the development of MS associated disabilities and therapies used. In need of almost constant catheterization. Use to compare outcomes in MS clinical trials.
The other authors declare that they have no conflicts of interest.
Also, using the EDSS and know disease duration, we classified each patient in the multiple sclerosis severity score MSSSusing the spread-sheet described by Roxburg et al.